Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Matthew Langer Meyerson, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Matthew Meyerson and Eric Lander.
Connection Strength

2.939
  1. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
    View in: PubMed
    Score: 0.579
  2. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer. 2014 Jun 04; 13:141.
    View in: PubMed
    Score: 0.155
  3. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
    View in: PubMed
    Score: 0.143
  4. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012 Sep 14; 150(6):1107-20.
    View in: PubMed
    Score: 0.137
  5. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9.
    View in: PubMed
    Score: 0.135
  6. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968.
    View in: PubMed
    Score: 0.128
  7. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
    View in: PubMed
    Score: 0.115
  8. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods. 2009 Jan; 6(1):99-103.
    View in: PubMed
    Score: 0.106
  9. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8.
    View in: PubMed
    Score: 0.098
  10. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science. 2007 Sep 14; 317(5844):1500.
    View in: PubMed
    Score: 0.097
  11. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct; 45(10):1113-20.
    View in: PubMed
    Score: 0.074
  12. Pathogen discovery from human tissue by sequence-based computational subtraction. Genomics. 2003 Mar; 81(3):329-35.
    View in: PubMed
    Score: 0.071
  13. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13790-5.
    View in: PubMed
    Score: 0.065
  14. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol. 2000 Sep; 18(9):1001-5.
    View in: PubMed
    Score: 0.060
  15. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017 07 06; 547(7661):55-60.
    View in: PubMed
    Score: 0.048
  16. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.042
  17. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
    View in: PubMed
    Score: 0.041
  18. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015 Mar; 25(3):316-27.
    View in: PubMed
    Score: 0.040
  19. The p53 pathway and ancestral progenitors are associated with tumor recurrence in glioblastoma. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii3.
    View in: PubMed
    Score: 0.039
  20. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23; 505(7484):495-501.
    View in: PubMed
    Score: 0.038
  21. The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10; 155(2):462-77.
    View in: PubMed
    Score: 0.037
  22. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218.
    View in: PubMed
    Score: 0.036
  23. Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77.
    View in: PubMed
    Score: 0.036
  24. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26.
    View in: PubMed
    Score: 0.035
  25. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013 Mar; 31(3):213-9.
    View in: PubMed
    Score: 0.035
  26. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar; 45(3):279-84.
    View in: PubMed
    Score: 0.035
  27. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 2013 Feb; 23(2):228-35.
    View in: PubMed
    Score: 0.035
  28. A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63.
    View in: PubMed
    Score: 0.034
  29. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May 20; 44(6):685-9.
    View in: PubMed
    Score: 0.034
  30. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6.
    View in: PubMed
    Score: 0.033
  31. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012 May; 30(5):413-21.
    View in: PubMed
    Score: 0.033
  32. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506.
    View in: PubMed
    Score: 0.033
  33. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60.
    View in: PubMed
    Score: 0.032
  34. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011 Jul 26; 108(30):12372-7.
    View in: PubMed
    Score: 0.032
  35. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
    View in: PubMed
    Score: 0.031
  36. The genomic complexity of primary human prostate cancer. Nature. 2011 Feb 10; 470(7333):214-20.
    View in: PubMed
    Score: 0.031
  37. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010 Aug; 42(8):715-21.
    View in: PubMed
    Score: 0.029
  38. Integrative analysis of the melanoma transcriptome. Genome Res. 2010 Apr; 20(4):413-27.
    View in: PubMed
    Score: 0.029
  39. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 05; 462(7269):108-12.
    View in: PubMed
    Score: 0.028
  40. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5.
    View in: PubMed
    Score: 0.026
  41. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008 Oct 23; 455(7216):1069-75.
    View in: PubMed
    Score: 0.026
  42. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12.
    View in: PubMed
    Score: 0.025
  43. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.